Zurich, Switzerland — (Startupticker) — 12/17/2013– Redbiotec announces a collaboration with GSK. This is another addition to an impressive list of partners including Merck and Roche.
Redbiotec AG, the technology leader in virus-like particle vaccines, with a successful track record including pharma customers and partners such as Roche and Merck amongst others, extends its network of partners.
Redbiotec announces a collaboration with GSK vaccines. This is another validation of Redbiotec’s technology platforfm rePAX and a major milestone after already being granted the prestigious Edufluvac project by EU earlier this year. In this collaboration, Redbiotec’s assets and its proprietary technology platform rePAX will be applied in a feasibility study by GSK for an undisclosed indication. Read more.